logo
Parkinson's Disease Has a Smell That Some Dogs Can Detect

Parkinson's Disease Has a Smell That Some Dogs Can Detect

Yahoo3 days ago
Dogs really can be trained to smell Parkinson's disease, according to new research from the United Kingdom.
In a double blind trial, a Golden Retriever and a Labrador were able to sniff out which skin swabs came from people with Parkinson's.
The smell of the oily secretions seemed to hold secret clues.
"The dogs in this study achieved high sensitivity and specificity and showed there is an olfactory signature distinct to patients with the disease," says animal behavioral scientist Nicola Rooney from the University of Bristol.
"Sensitivity levels of 70 percent and 80 percent are well above chance, and I believe that dogs could help us to develop a quick, non-invasive, and cost-effective method to identify patients with Parkinson's disease."
Related:
Today, there is no definitive early test for Parkinson's, which is why scientists are so interested in finding potential biomarkers of the disease on our skin.
The knowledge that Parkinson's distinctly changes a person's body odor first came to light roughly a decade ago – all because of one woman.
Twelve years before her husband's diagnosis of Parkinson's disease, Joy Milne could sense something was off – specifically, she could smell it.
Milne, a Scottish nurse, is known as a 'super-smeller', and in 2016, she became famous among neuroscientists for her extraordinary abilities.
In a small pilot study, Milne correctly identified each patient with Parkinson's disease based solely on the scent of their shirts. Her one misidentification turned out to be correct nearly a year later.
The news raised an important question: If someone like Milne could smell Parkinson's years before it was diagnosed, could a dog do the same?
Dogs are known to have incredible senses of smell, far more powerful than our own. Previous studies have found our pets can smell our stress, our coronavirus infections, and even our cancers – so if a distinct odor for Parkinson's does exist, then maybe a dog can sniff it out, too.
In the past decade, a few preliminary trials have provided evidence for that hypothesis. But some only gave limited information on how the dogs were trained and tested.
The recent trial from the UK is a collaboration between a program called Medical Detection Dogs and neuroscientists at the University of Manchester.
One goal of the research is to figure out what the dogs are actually smelling, and why.
In 2019, for instance, researchers at Manchester helped identify which odor compounds set the distinctive smell of Parkinson's apart. Their results were later confirmed by Milne, the serendipitous "super-smeller".
A few years on, the odor compounds were used to create a diagnostic 'swab test' for Parkinson's, currently in testing.
Perhaps, further down the road, trained dogs could help neuroscientists identify more unique biomarkers of the disease.
The trouble is, though, not all canines are up to snuff. In the current trial, only 2 out of 10 dogs made it through training, and neither performed perfectly.
One dog, for instance, falsely flagged a tenth of the odor swabs from healthy people as having Parkinson's. The other gave false alarms less than 2 percent of the time.
Overall, however, the dogs could smell which person had Parkinson's at a rate well above chance, providing proof of principle.
"We are extremely proud to say that once again, dogs can very accurately detect disease," says Claire Guest, the CEO of Medical Detection Dogs.
"There is currently no early test for Parkinson's disease and symptoms may start up to 20 years before they become visible and persistent leading to a confirmed diagnosis.
"Timely diagnosis is key… "
The study was published in the Journal of Parkinson's Disease.
Related News
Expert Reveals What Can Happen if Testosterone Gel Rubs Onto Others
Radioactive Waste Exposed Children in Missouri to Cancer Risks, Study Finds
A Single Brain Scan Halfway Through Your Life Can Reveal How Fast You're Aging
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Janssen's Darzalex new indication gains EC approval for SMM
Janssen's Darzalex new indication gains EC approval for SMM

Yahoo

time4 hours ago

  • Yahoo

Janssen's Darzalex new indication gains EC approval for SMM

The European Commission (EC) has approved the Johnson & Johnson company Janssen-Cilag International's new indication for Darzalex Faspro (daratumumab) subcutaneous (SC) formulation to treat adults with smouldering multiple myeloma (SMM) at high-risk of developing MM. Daratumumab is co-formulated with Halozyme's drug delivery technology, Enhanze. The EC approval is based on outcomes from the Phase III AQUILA study, which assessed the safety and efficacy of fixed-duration daratumumab SC administration against active monitoring in patients with high-risk SMM. The primary endpoint of the study is progression-free survival, while secondary endpoints encompass overall response rate, time to progression and overall survival. Patients included in the study had been diagnosed with SMM within the previous five years. Those with prior exposure to either approved or investigational treatments for SMM or multiple myeloma were excluded from participation. Halozyme president and CEO Dr Helen Torley stated: "This approval reinforces DARZALEX Faspro with ENHANZE as a foundational treatment across all stages of multiple myeloma. "We are pleased that the new treatment paradigm addresses the critical needs of people living with this complex blood disease." Halozyme's Enhanze drug delivery technology, featuring the enzyme rHuPH20, enables rapid SC delivery of drugs and fluids, enhancing patient experience and reducing treatment burden. It has been licensed to companies including Takeda, Roche, Pfizer, AbbVie and Acumen Pharmaceuticals. Johnson & Johnson innovative medicine multiple myeloma disease area leader and vice-president Jordan Schecter stated: 'Until now, there have been no approved treatment options for patients diagnosed with high-risk smouldering multiple myeloma. 'We can now offer physicians and patients the option to treat with daratumumab earlier, significantly delaying progression and the need for more intensive, continuous therapy, as well as extending overall survival.' "Janssen's Darzalex new indication gains EC approval for SMM" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Thousands of cancer cases could be prevented with more breast removal surgeries
Thousands of cancer cases could be prevented with more breast removal surgeries

Yahoo

time4 hours ago

  • Yahoo

Thousands of cancer cases could be prevented with more breast removal surgeries

Thousands of breast cancer cases could potentially be prevented if more women were offered 'risk reducing' breast removal surgery, a study suggests. Breast removal surgery, also known as a mastectomy, is offered to treat breast cancer in some women. It can also be offered to women who are deemed to be high risk of the disease to prevent them from getting it in the first place. A study has found that if more women were given preventative mastectomies, then about 6,500 cases of breast cancer could be prevented each year. Risk-reducing mastectomies (RRM) are currently only offered to women with the BRCA1, BRCA2, PALB2 genes, experts said. But the new analysis suggests that some women with other genes linked to a higher risk of breast cancer – including ATM, CHEK2, RAD51C, RAD51D – who may also be at higher risk due to a number of other factors may benefit from RRM if they are assessed as having a high risk of disease. These other factors can include a family history of breast cancer, the number of children they have had, whether or not they breast fed and mammogram density. Women in the UK have an 11% chance of developing breast cancer across their lifetime. Medics can calculate a woman's risk of breast cancer using tools which combine the effect of various risk factors. This is your breast check reminder! Learn the signs and symptoms of breast — Breast Cancer Now (@BreastCancerNow) May 6, 2025 Researchers from Queen Mary University of London and the London School of Hygiene and Tropical Medicine (LSHTM) found that if health officials could identify all women aged 30 to 55 who have a 35% or higher risk of breast cancer, and they all went on to have RRM, then an estimated 6,538 breast cancer cases could be prevented in the UK each year. This is the equivalent of around 11% of the 59,000 women in the UK who are diagnosed with breast cancer each year. The academics point out that women who have one of the other genes linked to breast cancer, who may be at high risk of disease, could potentially be found by a mechanism called 'cascade testing' – where genetic tests are offered to family members of women who have been found to have these different genes linked to breast cancer. The economic evaluation study, published in the journal JAMA Oncology, concludes: 'Undergoing RRM appears cost-effective for women at 30-55 years with a lifetime BC-risk 35% (or more). 'The results could have significant clinical implications to expand access to RRM beyond BRCA1/BRCA2/PALB2 pathogenic variant carriers.' Corresponding author on the paper, Professor Ranjit Manchanda, professor of gynaecological oncology at Queen Mary and consultant gynaecological oncologist, said: 'We for the first time define the risk at which we should offer RRM. 'Our results could have significant clinical implications to expand access to mastectomy beyond those patients with known genetic susceptibility in high penetrance genes- BRCA1/ BRCA2/ PALB2 – who are traditionally offered this. 'This could potentially prevent can potentially prevent (around) 6500 breast cancer cases annually in UK women. 'We recommend that more research is carried out to evaluate the acceptability, uptake, and long-term outcomes of RRM among this group'. Dr Rosa Legood, associate professor in health economics at LSHTM, added: 'Undergoing RRM is cost-effective for women (aged) 30 to 55-years with a lifetime breast cancer risk of 35% or more. 'These results can support additional management options for personalised breast cancer risk prediction enabling more women at increased risk to access prevention.' Women deemed to be at high risk of breast cancer can also be offered regular screening and medication. Louise Grimsdell, Breast Cancer Now senior clinical nurse specialist, said: 'While this modelling provides valuable insights into the cost-effectiveness of risk-reducing mastectomy for women with a high risk of developing breast cancer, each individual must be offered all risk-management options that are suitable for them. 'Choosing to have risk-reducing surgery is a complex and deeply personal decision that comes with emotional and physical implications. 'So, it's vital women can consider all their options, including screening and risk-reducing medications, and are supported by their clinician to make an informed decision that's right for them. 'It's also crucial that the unacceptably long waits that far too many women who chose risk-reducing surgery are facing are urgently tackled.'

New study reaches landmark conclusion about impact of wind turbines on human health: 'Not a cause-and-effect relationship'
New study reaches landmark conclusion about impact of wind turbines on human health: 'Not a cause-and-effect relationship'

Yahoo

time5 hours ago

  • Yahoo

New study reaches landmark conclusion about impact of wind turbines on human health: 'Not a cause-and-effect relationship'

New study reaches landmark conclusion about impact of wind turbines on human health: 'Not a cause-and-effect relationship' A new peer-reviewed study from researchers at Poland's Adam Mickiewicz University has found no evidence that wind turbine noise causes mental harm, putting to rest a persistent and unsubstantiated claim that clean energy projects may be harming our health. Medical Xpress reported that the study measured brainwave activity in 45 university students exposed to different sounds — including traffic, wind turbines, and silence — without revealing the sources. Participants described the turbine noise as white noise and did not report it as any more stressful than city traffic. The researchers also found no measurable differences in brain activity, nor any signs of psychological harm, across the various sound environments. "Although these results cannot be generalized, they support the concept that the interlinkage between exposure to wind turbine noise and human cognitive functioning is not a cause-and-effect relationship," the authors wrote in the study, published in the journal Humanities and Social Sciences Communications. While they acknowledged that their research is not definitive on long-term exposure, they concluded that "wind turbine syndrome" — the conspiracy theory suggesting these sounds cause cancer or mental illness — has no scientific basis. This is reassuring news for consumers and communities. Wind turbines are among the most cost-effective sources of clean energy and can offer great economic and health benefits. They reduce dependence on dirty energy sources like oil and gas, helping to curb rising health risks tied to air pollution. They can also help stabilize public energy grids and lower utility costs for homeowners. Plus, by reducing the amount of heat-trapping air pollution the energy industry generates, we're working toward a safer, cleaner future for all of us. Studies like this help cut through misinformation that could dampen public reception to clean power sources. "This interpretation is compatible with previous findings showing social contexts, such as socialization and misinformation, as a moderator of the interlinkage between wind turbine noise and human functioning," the study authors wrote. A discussion on Reddit shared similar viewpoints on the topic. "Colleague of mine [used] to do community engagement," one commenter said. "Received lots of calls about how the wind turbines were making people in the area sick. She had to tell them that the newly built turbines hadn't actually been switched on yet. Not saying some people weren't having a reaction though as the mind can be a powerful tool (look up the Nocebo effect)." Do you worry about air pollution in your town? All the time Often Only sometimes Never Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store